Cardiac Science (NASDAQ:DFIB)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Cardiac Science Charts. Click Here for more Cardiac Science Charts.](/p.php?pid=staticchart&s=N%5EDFIB&p=8&t=15)
City of St. Louis Selects Cardiac Science as Exclusive Provider
of AEDs for Public Access Defibrillation Program
St. Louis Joins a Growing List of Major U.S. Cities to Partner With Cardiac
Science on Comprehensive AED Deployment
IRVINE, Calif., Jan. 20 /PRNewswire-FirstCall/ -- Cardiac Science, Inc.
(NASDAQ:DFIB), a leading manufacturer of life-saving automatic public-access
defibrillators (AEDs), announced today that it has been selected as the
exclusive provider of AEDs and comprehensive AED/CPR training and AED program
management services for a city-wide Public Access Defibrillator (PAD) program
launched by the City of St. Louis, Missouri. To initiate the program,
approximately 90 Powerheart(R) AED G3s were purchased from Cardiac Science. St.
Louis's new PAD program makes it the latest major U.S. city to partner with
Cardiac Science, joining San Diego, Minneapolis, Miami and Nashville.
"The St. Louis Project Heartbeat" PAD program, which has been approved by the
City of St. Louis and Mayor Francis G. Slay, seeks to provide this life saving
technology to all its citizens, guests and employees.
The PAD program is being coordinated by the St. Louis Fire Department, which in
addition to planning the deployment of AEDs, is reaching out to private
citizens and organizations through a public awareness campaign on the
importance of defibrillation therapy and the use of AEDs to treat victims of a
massive heart attack, also called sudden cardiac arrest ("SCA").
According to St. Louis Fire Commissioner and Chief Sherman George, the goal of
the PAD project is to significantly increase local community cardiac arrest
survival rates by making AEDs more accessible in a wide variety of settings and
educating citizens about the Chain of Survival, an emergency intervention
process that includes early defibrillation and CPR.
"The St. Louis Fire Department has focused on injury and illness prevention in
many community outreach programs. This program aims to dramatically improve
SCA survival rates in St. Louis," said Chief George. "This program is
beneficial not only to our citizens but to our fellow firefighters as well.
Heart attacks and SCA remain the number one killers of firefighters today.
"Our goal is to deploy hundreds of AEDs in public facilities, highly trafficked
public places and businesses throughout St. Louis within the next few years,"
continued George. "This is a true partnership and we look forward to working
with Cardiac Science in this effort. We chose Cardiac Science based on a
number of factors. We were impressed with their comprehensive program and a
demonstrable track record of PAD program successes in other cities. In
addition, we conducted an extensive review of all AED products in the market
and found that Cardiac Science's Powerheart AEDs are robust, reliable, and very
easy to use and best suited the needs of the St. Louis Fire Department."
About Cardiac Science
Cardiac Science develops, manufactures and markets Powerheart(R)-brand
public-access defibrillators (AEDs) and offers comprehensive AED/CPR training
and AED program management services that facilitate successful deployments. The
Company also makes its AEDs on a private label basis for other leading medical
companies such as Nihon Kohden (Japan), Quinton Cardiology Systems and GE
Healthcare. For more information, please visit http://www.cardiacscience.com/,
email Cardiac Science at or call 1-949-797-3800.
This news release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. In addition, from time
to time the company, or its representatives, have made or may make forward
looking statements orally or in writing. The words "estimate," "potential,"
"intended," "expect," "anticipate," "believe," and similar expressions or words
are intended to identify forward looking statements. Cardiac Science cautions
that these statements are subject to substantial risks and uncertainties and
are qualified by important factors that could cause actual results to differ
materially from those reflected by the forward- looking statements and should
not be relied upon by investors when making an investment decision.
Information on these and other factors is detailed in the Company's Form 10-K
for the year ending December 31, 2003, subsequent quarterly filings, and other
documents filed by the Company with the Securities and Exchange Commission.
For further information please contact: Matt Clawson (Investors), Allen & Caron
Inc, +1-949-474-4300, , for Cardiac Science, Inc.; or Michael D. Gioffredi,
Chief Marketing Officer of Cardiac Science, Inc., +1-949-797-3800,
DATASOURCE: Cardiac Science, Inc.
CONTACT: Matt Clawson (Investors), Allen & Caron Inc, +1-949-474-4300,
, for Cardiac Science, Inc.; or Michael D. Gioffredi, Chief
Marketing Officer of Cardiac Science, Inc., +1-949-797-3800,
Web site: http://www.cardiacscience.com/